A Randomized Comparison Of Medroxyprogesterone Acetate (MA) And Observation For Prevention Of Endometrial Pathology In Postmenopausal Breast Cancer Patients Treated With Tamoxifen, Phase III.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Medroxyprogesterone (Primary) ; Tamoxifen
- Indications Endometrial cancer; Endometrial hyperplasia
- Focus Therapeutic Use
- 31 Oct 2012 Biomarkers information updated
- 17 Jun 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 07 Sep 2005 New trial record.